PARP1 and cancer: Since some PARP inhibitors such as olaparib are being used in the clinic for the treatment of other cancers, combining PARPi with 177Lu-octreotate could rapidly offer a new opportunity for boosting the efficacy of PRRT in patients suffering from NET.